Fingolimod
- Generic Name
- Fingolimod
- Brand Names
- Gilenya, Tascenso, Fingolimod Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C19H33NO2
- CAS Number
- 162359-55-9
- Unique Ingredient Identifier
- 3QN8BYN5QF
- Background
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was a...
- Indication
Fingolimod is indicated for the treatment of patients aged 10 and above with relapsing forms of multiple sclerosis, which may include clinically isolated syndrome, relapsing-remitting disease, as well as active secondary progressive disease.
- Associated Conditions
- Relapsing Multiple Sclerosis (RMS)
- Associated Therapies
- Alternative Treatment
Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation
Phase 3
Completed
- Conditions
- First Posted Date
- 2004-12-08
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 140
- Registration Number
- NCT00098735
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath